Literature DB >> 24704691

Novel merosesquiterpene exerts a potent antitumor activity against breast cancer cells in vitro and in vivo.

Esther Carrasco1, Pablo Juan Álvarez2, Consolación Melguizo2, José Prados2, Enrique Álvarez-Manzaneda3, Rachid Chahboun3, Ibtissam Messouri3, María Isabel Vázquez-Vázquez2, Antonia Aránega2, Fernando Rodríguez-Serrano4.   

Abstract

This article describes the antitumor properties of a new family of merosesquiterpenes, which were synthesized by Diels-Alder cycloaddition of the labdane diene trans-communic acid, highly abundant in Cupressus sempervirens, or its methyl ester, with the appropriate dienophile. These compounds demonstrated potent cytotoxic activity in vitro against human breast, colon, and lung tumor cells. We highlight the elevated activity (IC50: 0.35 ± 0.10 μM) and specificity (TI: 9) of compound 13 against the MCF-7 line, which corresponds to the most prevalent breast cancer cell subtype, luminal A. It was found that compound 13 exerts its anti-tumor action by inducing oxidative stress, arresting the cell cycle in stages G0-G1, and activating apoptosis, which are all associated with low cyclin D1 regulation, pRb hypophosphorylation, increased expression of p27 and p53, and poly (ADP-ribose) polymerase (PARP) fractioning. Epithelial-mesenchymal transition, a phenomenon associated with metastasis promotion and a worsened prognosis also appeared to be inhibited by compound 13. In addition, it markedly reduced tumor development in immunocompetent C57BL/6 mice with allografts of E0771 mouse breast tumor cells (luminal A subtype). According to these findings, this new family of compounds, especially compound 13, may be highly useful in the treatment of human breast cancer.
Copyright © 2014 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Allografts; Apoptosis; Cancer; Cell cycle arrest; Merosesquiterpene; Oxidative stress

Mesh:

Substances:

Year:  2014        PMID: 24704691     DOI: 10.1016/j.ejmech.2014.03.071

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  8 in total

Review 1.  Exosomes Derived from Breast Cancer Cells, Small Trojan Horses?

Authors:  Alejandro Villagrasa; Pablo Juan Álvarez; Antonio Osuna; Jose Manuel Garrido; Antonia Aránega; Fernando Rodríguez-Serrano
Journal:  J Mammary Gland Biol Neoplasia       Date:  2015-07-01       Impact factor: 2.673

Review 2.  Antioxidant Intake and Antitumor Therapy: Toward Nutritional Recommendations for Optimal Results.

Authors:  Nuria Mut-Salud; Pablo Juan Álvarez; Jose Manuel Garrido; Esther Carrasco; Antonia Aránega; Fernando Rodríguez-Serrano
Journal:  Oxid Med Cell Longev       Date:  2015-11-22       Impact factor: 6.543

3.  Biological Evaluation and Docking Studies of Synthetic Oleanane-type Triterpenoids.

Authors:  Mariano Ortega-Muñoz; Fernando Rodríguez-Serrano; Eduardo De Los Reyes-Berbel; Nuria Mut-Salud; Fernando Hernández-Mateo; Andrea Rodríguez-López; José M Garrido; F Javier López-Jaramillo; Francisco Santoyo-González
Journal:  ACS Omega       Date:  2018-09-20

Review 4.  Comprehensive Review of Methodology to Detect Reactive Oxygen Species (ROS) in Mammalian Species and Establish Its Relationship with Antioxidants and Cancer.

Authors:  Shivkanya Fuloria; Vetriselvan Subramaniyan; Sundram Karupiah; Usha Kumari; Kathiresan Sathasivam; Dhanalekshmi Unnikrishnan Meenakshi; Yuan Seng Wu; Mahendran Sekar; Nitin Chitranshi; Rishabha Malviya; Kalvatala Sudhakar; Sakshi Bajaj; Neeraj Kumar Fuloria
Journal:  Antioxidants (Basel)       Date:  2021-01-18

5.  Functionalized immunostimulating complexes with protein A via lipid vinyl sulfones to deliver cancer drugs to trastuzumab-resistant HER2-overexpressing breast cancer cells.

Authors:  Fernando Rodríguez-Serrano; Nuria Mut-Salud; Teresa Cruz-Bustos; Mercedes Gomez-Samblas; Esther Carrasco; Jose Manuel Garrido; F Javier López-Jaramillo; Francisco Santoyo-Gonzalez; Antonio Osuna
Journal:  Int J Nanomedicine       Date:  2016-09-19

6.  Meroxest improves the prognosis of immunocompetent C57BL/6 mice with allografts of E0771 mouse breast tumor cells.

Authors:  Esther Carrasco; Jose Manuel Garrido; Pablo Juan Álvarez; Enrique Álvarez-Manzaneda; Rachid Chahboun; Ibtissam Messouri; Consolación Melguizo; Antonia Aránega; Fernando Rodríguez-Serrano
Journal:  Arch Med Sci       Date:  2016-03-31       Impact factor: 3.318

7.  Dysregulation of metabolic-associated pathways in muscle of breast cancer patients: preclinical evaluation of interleukin-15 targeting fatigue.

Authors:  Joseph Bohlen; Sarah L McLaughlin; Hannah Hazard-Jenkins; Aniello M Infante; Cortney Montgomery; Mary Davis; Emidio E Pistilli
Journal:  J Cachexia Sarcopenia Muscle       Date:  2018-03-26       Impact factor: 12.910

Review 8.  EO771, is it a well-characterized cell line for mouse mammary cancer model? Limit and uncertainty.

Authors:  Augustin Le Naour; Adrien Rossary; Marie-Paule Vasson
Journal:  Cancer Med       Date:  2020-10-07       Impact factor: 4.452

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.